Cytokinetics to Announce First Quarter Results on May 9, 2019
26 April 2019 - 6:00AM
Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is
scheduled to report first quarter results on May 9, 2019 at 4:00 PM
Eastern Time. Following the announcement, Cytokinetics’ senior
management will host a conference call at 4:30 PM Eastern Time to
discuss operational and financial results and the company’s outlook
for the future.
The conference call will be simultaneously
webcast and can be accessed from the homepage and in the Investors
& Media section of Cytokinetics’ website at
www.cytokinetics.com. The live audio of the conference call can
also be accessed by telephone by dialing either (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 4486595.
An archived replay of the webcast will be
available via Cytokinetics’ website until May 16, 2019. The replay
will also be available via telephone by dialing (855) 859-2056
(United States and Canada) or (404) 537-3406 (international) and
typing in the passcode 4486595 from May 9, 2019 at 7:30 PM Eastern
Time until May 16, 2019.
About Cytokinetics
Cytokinetics is a late-stage biopharmaceutical
company focused on discovering, developing and commercializing
first-in-class muscle activators and best-in-class muscle
inhibitors as potential treatments for debilitating diseases in
which muscle performance is compromised and/or declining. As a
leader in muscle biology and the mechanics of muscle performance,
the company is developing small molecule drug candidates
specifically engineered to impact muscle function and
contractility. Cytokinetics is collaborating with Amgen Inc.
(Amgen) to develop omecamtiv mecarbil, a novel cardiac muscle
activator. Omecamtiv mecarbil is the subject of an international
Phase 3 clinical trials program including GALACTIC-HF and
METEORIC-HF. Amgen holds an exclusive worldwide license to develop
and commercialize omecamtiv mecarbil with a sublicense held by
Servier for commercialization in Europe and certain other
countries. Cytokinetics is collaborating with Astellas Pharma Inc.
(Astellas) to develop reldesemtiv, a fast skeletal muscle troponin
activator (FSTA). Reldesemtiv has been granted orphan drug
designation by the FDA for the potential treatment of spinal
muscular atrophy. Reldesemtiv was the subject of a Phase 2 clinical
study in patients with spinal muscular atrophy which showed
increases in measures of endurance and stamina consistent with the
mechanism of action. Reldesemtiv is currently the subject of a
Phase 2 clinical trial in patients with amyotrophic lateral
sclerosis. Astellas holds an exclusive worldwide license to develop
and commercialize reldesemtiv. Licenses held by Amgen and Astellas
are subject to specified co-development and co-commercialization
rights of Cytokinetics. Cytokinetics is also developing CK-274, a
novel cardiac myosin inhibitor that company scientists discovered
independent of its collaborations, for the potential treatment of
hypertrophic cardiomyopathies. Cytokinetics continues its over
20-year history of pioneering innovation in muscle biology and
related pharmacology focused to diseases of muscle dysfunction and
conditions of muscle weakness.
For additional information
about Cytokinetics, visit www.cytokinetics.com and follow
us on Twitter, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995 (the "Act"). Cytokinetics disclaims any
intent or obligation to update these forward-looking statements,
and claims the protection of the Act's Safe Harbor for
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating
to Cytokinetics' and its partners' research and
development activities of Cytokinetics’ product candidates. Such
statements are based on management's current expectations, but
actual results may differ materially due to various risks and
uncertainties, including, but not limited to the risks related
to Cytokinetics' business outlined
in Cytokinetics' filings with the Securities and
Exchange Commission. Forward-looking statements are not guarantees
of future performance, and Cytokinetics' actual results
of operations, financial condition and liquidity, and the
development of the industry in which it operates, may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements
that Cytokinetics makes in this press release speak only
as of the date of this press
release. Cytokinetics assumes no obligation to update its
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press
release.
Contact:CytokineticsDiane WeiserVice President, Corporate
Communications, Investor Relations(650) 624-3060
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2024 to May 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2023 to May 2024